Rothschild & Co Redburn initiated coverage of Regeneron (REGN) with a Buy rating and $890 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron’s Latest Clinical Trial: A New Hope for Advanced Cancer Treatment
- Regeneron’s Cemiplimab Study: A Potential Game-Changer for Skin Cancer Treatment
- Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game-Changer?
- Regeneron price target lowered to $812 from $940 at Truist
- Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Asthma Treatment